Welcome to the e-CCO Library!

DOP55: Histopathological features at diagnosis to predict long-term disease course of Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Rezazadeh Ardabili, A.(1,2);Goudkade, D.(3);Wintjens, D.S.J.(1,2);Romberg-Camps, M.J.L.(4);Winkens, B.(5);Pierik, M.J.(1,2);Grabsch, H.I.(6,7);Jonkers, D.M.A.E.(1,2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP55: Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Leong, R.(1);Sands, B.(2);Peyrin-Biroulet, L.(3);Marano, C.(4);Miao, Y.(4);Izanec, J.(5);Feagan, B.(6);Rubin, D.(7); UNIFI Investigators
Created: Friday, 11 February 2022, 3:52 PM
DOP55: The increasing burden of direct and indirect costs of IBD
Year: 2023
Source: ECCO’23 Copenhagen
Authors: BurischPhD, J.(1)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. S. Jung*1,2, K-w. Choi3, S. W. Kim2, M. Hübenthal1, S. Mucha1, J. Park2, Z. Park3, D. Ellinghaus1, S. Schreiber1, A. Franke1, W. Y. Oh3, J. H. Cheon2

Created: Friday, 22 February 2019, 9:41 AM
DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W.J. Sandborn1, D.S. Rowbotham2, R.W.L. Leong3, C. Han4, Y. Zhou5, H. Zhang5, J. Johanns5, C. Marano6, S. Danese7, UNIFI Investigators

Created: Thursday, 30 January 2020, 10:12 AM
DOP56: Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Strik*1,2, S. Berends3, D. Mould4, R. Mathôt3, C. Ponsioen2, J. van den Brande5, J. Jansen6, D. Hoekman7, J. Brandse8, M. Löwenberg2, G. D'Haens2

Created: Friday, 22 February 2019, 9:41 AM
DOP56: has been withdrawn
Year: 2021
Source: ECCO'21 Virtual
Created: Wednesday, 2 June 2021, 4:12 PM
DOP56: Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Reinisch, W.(1);De Hertogh, G.(2);Protic, M.(3);Chan, L.S.(3);Magro, F.(4);Pollack, P.(3);Feagan, B.G.(5);Harpaz, N.(6);Pai, R.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP56: Long-term disease progression and resective surgery rates in Crohn's disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gonczi, L.(1);Lakatos, L.(2)*;Golovics, P.A.(3);Pandur, T.(4);David, G.(2);Erdélyi, Z.(2);Szita, I.(2);LakatosPhD, P.L.(5);
Created: Friday, 14 July 2023, 10:43 AM
DOP57 Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicentre, retrospective case–control study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N.A. Cohen1,2, N. Plevris3, U. Kopylov2,4, A. Grinman2,4, B. Ungar1,2, H. Yanai2,5, H. Leibovitzh2,5, N. Fliss1,2, A. Hirsch1,2, E. Ritter1,2, Y. Ron1,2, A. Bar-Gil Shitrit6,7, E. Goldin6,7, I. Dotan2,5, S. Ben-Horin2,4, C. Lees3,8, N. Maharshak1,2

Created: Thursday, 30 January 2020, 10:12 AM
DOP57: Development and validation of a convolutional neural network for the automatic detection of enteric ulcers and erosions in capsule endoscopy: A multicentric study
Year: 2022
Source: ECCO'22
Authors: Afonso , J.(1);Mascarenhas , M.(1);Ribeiro , T.(1);Cardoso , P.(1);Gonçalves , R.(1);Ferreira , J.(2);Andrade , A.P.(1);Mascarenhas Saraiva , M.(3);Cardoso , H.(1);Macedo , G.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP57: GLP-1 based therapies and risk of Inflammatory Bowel Disease: real world evidence from a nationwide cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Christensen, H.S.(1)*;Andersen, D.(2);Jess, T.(2);Allin, K.H.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST&UC
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Maaser*1, F. Petersen1, U. Helwig2, I. Fischer3, S. Rath4, S. Kolterer4, D. Lang4, T. Kucharzik1

Created: Friday, 22 February 2019, 9:41 AM
DOP57: Predictive modelling to examine long term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Maruszczak, M.(1);Genenz, K.(2);Turkstra, E.(3);Fenu, E.(2);Hantsbarger, G.(4);Gilaberte, I.(5);Karki, C.(6);Panes, J.(7)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP58 Tofacitinib for ulcerative colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V.B. Biemans1, J.A.M. Sleutjes2, A.C. de Vries2, A.G. Bodelier3, G. Dijkstra4, B. Oldenburg5, M. Löwenberg6, A.A. van Bodegraven7, A.E. van der Meulen-de Jong8, N.K. de Boer9, N. Srivastava10, R.L. West11, T. Römkens12, C.S. Horjus Talabur Horje13, J.M. Jansen14, J. Hoekstra3, R.K. Weersma4, F.D. van Schaik5, F. Hoentjen1, M.J. Pierik15, Dutch Initiative on Crohn and Colitis (ICC)

Created: Thursday, 30 January 2020, 10:12 AM
DOP58: An artificial intelligence–driven scoring system to measure histological disease activity in Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Peyrin-Biroulet, L.(1);Adsul, S.(2);Dehmeshki, J.(3);Kubassova, O.(3);
Created: Friday, 11 February 2022, 3:52 PM
DOP58: IdeaL: a multi-centre prospective infliximab dose to level pharmacokinetic study during induction in paediatric Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. H. Huynh*1, M. W. Carroll1, A. M. Griffiths2, W. El-Matary3, A. Petrova4, C. Prosser5, C. Kluthe6, J. C. deBruyn7, D. Tomalty2, D. R. Mould8, E. Wine4, H. Q. Huynh4

Created: Friday, 22 February 2019, 9:41 AM
DOP58: Non-white race is associated with decreased efficacy of tumor necrosis factor antagonist therapy in Ulcerative Colitis: A post-hoc analysis of individual level data from golimumab clinical trials
Year: 2021
Source: ECCO'21 Virtual
Authors: Greywoode, R.(1);Petralia, F.(2);Ullman, T.(1);Colombel, J.F.(3);Ungaro, R.(3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP58: predictors of complicated disease course in CD in an administrative database: a nationwide study from the epi-IIRN
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lujan, R.(1);Atia, O.(1);Gili, F.(1)*;Greenfeld, S.(2);Kariv, R.(2);Loewenberg Weisband, Y.(3);Lederman, N.(4);Matz, E.(5);Dotan, I.(6);Turner, D.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.F. Colombel1, M.T. Osterman2, P. Ibanez3, A.J. Thorpe4, H. Zhang4, N. Lawendy4, C. Su4, W. Reinisch5

Created: Thursday, 30 January 2020, 10:12 AM